Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Sirukumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SIRROUND-D
- Sponsors Janssen Research & Development
- 23 Sep 2020 Results of retrospective analysis by using data from four phase III studies (SIRROUND- D, SIRROUND-T, GO-BEFORE and GO-FORWARD) presented at the 2020 American College of Clinical Pharmacology Annual Meeting.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 14 Jun 2018 Results of an exposure-response modelling analysis from SIRROUND-D and SIRROUND-T studies, published in the Journal of Clinical Pharmacology.